Pan Chin-Chen, Chen Paul Chih-Hsueh, Chou Teh-Ying, Chiang Hung
Department of Pathology, National Yang-Ming University and Veterans General Hospital, Taipei, Taiwan.
Hum Pathol. 2003 Nov;34(11):1155-62. doi: 10.1053/j.humpath.2003.07.002.
Thymic carcinoma and thymoma are primary neoplasms of the anterior mediastinum that can involve the lung and pleura in advanced stages or, in rare instances, occur as primary pleural tumors. Thus these tumors may be encountered in thoracic and pleural biopsy specimens. Recognizing the immunohistochemical patterns of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma may be helpful in avoiding confusion with malignant mesothelioma and pulmonary carcinoma, both of which are major differential diagnoses in this location. Accordingly, in the present study we examined the expression of calretinin, mesothelin, cytokeratin (CK) 5/6, thrombomodulin, HBME-1, Wilms' tumor-1 (WT-1), Ber-EP4, MOC-31, BG-8, B72.3, carcinoembryonic antigen (CEA), CD15, thyroid transcription factor-1 (TTF-1), p63, and CD5 in 22 thymic carcinomas and 35 thymomas, and compared the results with those of malignant mesothelioma and pulmonary adenocarcinoma. Around 1/3 of thymic carcinomas were positive for calretinin and/or mesothelin. Both thymic carcinomas and thymomas were frequently positive for CK 5/6. Immunoreactivity for HBME-1 was seen in 4 thymic carcinomas and 10 thymomas. Except for 1 thymic carcinoma being positive for WT-1, all other thymic carcinomas and thymomas were negative for WT-1 and thrombomodulin. None of the thymic carcinomas and thymomas expressed TTF-1. More than 70% of the thymic carcinomas were positive for Ber-EP4, BG-8, and CD15. The positive rates of MOC-31, B72.3, and CEA in thymic carcinomas were in the middle between those in mesothelioma and pulmonary adenocarcinoma. All thymic epithelial tumors revealed nuclear immunoreactivity for p63. Nine thymic carcinomas (41%) expressed CD5. We found that a panel of positive p63, negative thrombomodulin, WT-1, and TTF-1 is most discriminatory for thymic epithelial tumors. Other mesothelial (calretinin and mesothelin) and epithelial (Ber-EP4, BG-8, and CD15) markers are less contributory in discerning thymic epithelial tumors due to their overlapping expression with malignant mesothelioma and pulmonary adenocarcinoma. Given the complexity of the staining patterns among the different entities, proper immunohistochemical stainings should be selected and interpreted with caution, and correlated with clinicopathologic findings in the differential diagnoses of thoracic biopsy specimens.
胸腺癌和胸腺瘤是前纵隔的原发性肿瘤,晚期可累及肺和胸膜,或在罕见情况下,可作为原发性胸膜肿瘤出现。因此,这些肿瘤可能出现在胸壁和胸膜活检标本中。认识到胸腺癌和胸腺瘤中钙视网膜蛋白及其他间皮瘤相关标志物的免疫组化模式,可能有助于避免与恶性间皮瘤和肺癌混淆,这两种肿瘤都是该部位主要的鉴别诊断对象。因此,在本研究中,我们检测了22例胸腺癌和35例胸腺瘤中钙视网膜蛋白、间皮素、细胞角蛋白(CK)5/6、血栓调节蛋白、HBME-1、威尔姆斯瘤-1(WT-1)、Ber-EP4、MOC-31、BG-8、B72.3、癌胚抗原(CEA)、CD15、甲状腺转录因子-1(TTF-1)、p63和CD5的表达,并将结果与恶性间皮瘤和肺腺癌的结果进行比较。约1/3的胸腺癌钙视网膜蛋白和/或间皮素呈阳性。胸腺癌和胸腺瘤CK 5/6均常呈阳性。4例胸腺癌和10例胸腺瘤可见HBME-1免疫反应性。除1例胸腺癌WT-1呈阳性外,所有其他胸腺癌和胸腺瘤WT-1和血栓调节蛋白均为阴性。胸腺癌和胸腺瘤均不表达TTF-1。超过70%的胸腺癌Ber-EP4、BG-8和CD15呈阳性。胸腺癌中MOC-31、B72.3和CEA的阳性率介于间皮瘤和肺腺癌之间。所有胸腺瘤上皮肿瘤p63均呈核免疫反应性。9例胸腺癌(41%)表达CD5。我们发现,一组p63阳性、血栓调节蛋白、WT-1和TTF-1阴性对胸腺瘤上皮肿瘤最具鉴别意义。其他间皮(钙视网膜蛋白和间皮素)和上皮(Ber-EP4、BG-8和CD15)标志物在鉴别胸腺瘤上皮肿瘤方面作用较小,因为它们与恶性间皮瘤和肺腺癌表达重叠。鉴于不同实体染色模式的复杂性,应谨慎选择和解释合适的免疫组化染色,并与胸壁活检标本鉴别诊断中的临床病理结果相关联。